Amidst the reports of shortage of Amphotericin B, a drug used to treat black fungus, the Centre on Saturday provided an allocation of additional vials of the drug.
In recent times a new challenge in the form of a fungal infection namely Mucormycosis has emerged and is reported from many states amongst COVID 19 patients especially those on steroid therapy and deranged sugar control. This fungal infection is leading to prolonged morbidity and mortality amongst COVID 19 patients.
The rare fungal infection called 'mucormycosis' or 'black fungus' is on the rise in several parts of the country.
Check how many vials of Amphotericin B will be given to your state:
People catch mucormycosis by coming in contact with the fungal spores in the environment. It can also develop on the skin after the fungus enters the skin through a cut, scrape, burn, or other types of skin trauma.
The Union Health Ministry on Thursday in a letter to States and Union Territories has asked to make Mucormycosis or black fungus a notifiable disease under the Epidemic Diseases Act 1897.
In the letter accessed by ANI, the Ministry states, "The treatment of this fungal infection requires multidisciplinary approach consisting of Eye Surgeons, ENT specialists, General Surgeon, Neurosurgeon, Dental Maxillofacial surgeon etc. and institution of Amphotericin B as an antifungal medicine. You are requested to make mucormycosis a notifiable disease under Epidemic Diseases Act 1897." Under this, all government and private health facilities, medical colleges will follow guidelines for screening, diagnosis, management of mucormycosis, issued by the union health ministry and Indian Council of Medical Research (ICMR).
The ministry also asked to make it mandatory for all these facilities to report all suspected and confirmed cases to Health Department through the district level Chief Medical Officer and subsequently to the Integrated Disease Surveillance Project (IDSP) surveillance system.
(With inputs from ANI)